ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 1793 • ACR Convergence 2023

    Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis

    Amy Cameron1, Rabina Giri2, Jakob Begun2, Timothy Wells1, Ranjeny Thomas3 and Anne-Sophie Bergot1, 1Frazer Institute, The University of Queensland, Woolloongabba, Australia, 2Mater Research Institute-UQ, Woolloongabba, Australia, 3Frazer Institute, The University of Queensland, Brisbane, Australia

    Background/Purpose: The loss of intestinal barrier integrity is a key contributor to gut inflammation, however the mechanism behind this dysregulation is not well understood. The…
  • Abstract Number: 0574 • ACR Convergence 2023

    Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE

    Kanwal Zahid Siddiqi1, Amanda Hempel Zinglersen2, Katrine Kjær Iversen1 and Søren Jacobsen2, 1Copenhagen Research Center for Autoimmune Connective Tissue Diseases (COPEACT), Department of Rheumatology 4242, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark, 2Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Aberrant activation of type I IFN, and subsequent adverse clinical implications, have been widely discussed in relation to SLE. With the lack of consistent…
  • Abstract Number: 1173 • ACR Convergence 2023

    Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease

    Toshimasa Shimizu1, Haruna Matsuo2, Tomohiro Koga3, Noriho Sakamoto4, Hiroshi Mukae1 and Atsushi Kawakami1, 1Nagasaki University, Nagasaki, Japan, 2Nagasaki University, Nagasaki City, Japan, 3Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, 4Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a chronic inflammatory disorder involved in skeletal muscles. Interstitial lung disease (ILD) as an organ lesion is a common…
  • Abstract Number: 2042 • ACR Convergence 2023

    Intraocular Cytokine Profiling of Autoimmune Uveitis

    Maryrose Hahn1, Madison Mangin2, Marc Todd1, Pui Lee1, Mindy Lo1, Bharti Gangwani3, Ankoor Shah3, Amanda Colombo4, Jessica Scott4, Stephen Anesi4, C. Stephen Foster4, Peter Chang4, Peter Nigrovic2 and Margaret Chang2, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Boston, MA, 3Department of Ophthalmology, Boston Children's Hospital, Boston, MA, 4Massachusetts Eye Research and Surgery Institution, Waltham, MA

    Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
  • Abstract Number: 0728 • ACR Convergence 2023

    Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype

    Diana Alzamareh, Mary O'Connell, Jennifer Anolik and Jennifer Barnas, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematous (SLE) is a heterogenous autoimmune disorder characterized by pathogenic antinuclear antibodies. An interferon (IFN) gene signature and B cell aberrations are…
  • Abstract Number: 1176 • ACR Convergence 2023

    Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis

    Jiri Vencovsky1, Jolie Feldman2, Lisa McConnachie2 and Brendan M. Johnson2, 1Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Priovant Therapeutics, Durham, NC

    Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
  • Abstract Number: 2096 • ACR Convergence 2023

    Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure

    Elizabeth Park1, Kazato Ito2, Christopher Depender1, Jon Giles3 and Joan Bathon3, 1Columbia University Irving Medical Center, New York, NY, 2Columbia University Medical Center, New York, NY, 3Columbia University, New York, NY

    Background/Purpose: Elevated left ventricular (LV) mass (LVM) is an important precursor to clinical heart failure (HF) in the general population. In fact, rheumatoid arthritis (RA)…
  • Abstract Number: 0771 • ACR Convergence 2023

    A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis

    Brent Luedders1, Dana Ascherman2, Daniel Kass3, Joshua Baker4, Michael Duryee1, Yangyuna Yang1, Punyasha Roul1, K Wysham5, Paul Monach6, Andreas Reimold7, Gail Kerr8, Gary Kunkel9, Grant Cannon10, Jill Poole1, Geoffrey Thiele1, Ted R Mikuls11 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Pennsylvania, Philadelphia, PA, 5VA Puget Sound/University of Washington, Seattle, WA, 6VA Boston Healthcare System, Boston, MA, 7University of Texas Southwestern Medical Center, Dallas, TX, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9University of Utah, Salt Lake City, UT, 10University of Utah and Salt Lake City VA, Salt Lake City, UT, 11Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Based on the overlap in peripheral blood biomarkers associated with rheumatoid arthritis interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), a composite biomarker…
  • Abstract Number: 1329 • ACR Convergence 2023

    R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis

    Yan Chen1, Sothy Yi1, Vadim Markovtsov1, Bhushan Samant1, Andrew Chow1, Esteban Masuda1 and Simon Shaw2, 1Rigel Pharmaceuticals, Inc, South San Francisco, CA, 2Rigel Pharmaceuticals, Inc., South San Francisco, CA

    Background/Purpose: The Toll-Like Receptor family (except TLR3) signal through IRAK4 and IRAK1 to produce an array of cytokines (including IL-6, IL-23 and TNFα in response…
  • Abstract Number: 2119 • ACR Convergence 2023

    Serum Alarmin Concentrations and Risk of Incident Major Adverse Cardiovascular Events and Heart Failure in a Multicenter, Prospective Rheumatoid Arthritis Cohort

    Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Michael Duryee1, Carlos Hunter1, Joshua Baker2, Brian Sauer3, Grant Cannon4, Amy Joseph5, K Wysham6, Aleksander Lenert7, Geoffrey Thiele1, Jill Poole1, Ted R Mikuls8 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Washington University / St. Louis VA, St. Louis, MO, 6VA Puget Sound/University of Washington, Seattle, WA, 7University of Iowa, Iowa City, IA, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Alarmins are endogenous cytokines released following cellular damage and physiologic stress to promote homeostasis through tissue inflammation, remodeling, and fibrosis. Alarmins may facilitate maladaptive…
  • Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium

    Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?

    Gleice Clemente1, Maria Teresa Terreri2, Bruno Gualano3, Clovis Silva4 and Alexandre Wagner De Souza1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2UNIFESP, São Paulo, Brazil, 3Universidade de São Paulo, São Paulo, 4Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
  • Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium

    Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors

    Itay Marmor1, Rotem Semo Oz2, Amir hendel3, Guy Hazan4, Kevin Baszis5, Anthony French5, Cuoghi Edens6, Irit Tirosh7, Yonatan Butbul Aviel8, Liora Harel9 and Gil Amarilyo10, 1Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 2Sheba medical center, Herzelyia, Israel, 3Tel Aviv University, Tel Aviv, Israel, 4Soroka University Medical Center, Be'er Sheva, Israel, 5Washington University School of Medicine, St Louis, MO, 6University of Chicago, Chicago, IL, 7Sheba Medical Center, Savyon, Israel, 8Rambam Medical center, Haifa, Israel, 9Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, 10Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
  • Abstract Number: 034 • 2023 Pediatric Rheumatology Symposium

    STAT3 Gain-of-function Syndrome Mutations Are Susceptible to JAK Inhibition Despite a Spectrum of Potency

    Herda Ona1, Justin Branch2, Isabella Osuna1, Priscilla vasquez2, Anaid Reyes1, Phillip Baker1, Michael Clowers1, Stephanie Wood1 and Tiphanie Vogel1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: STAT3 gain-of-function (GOF) syndrome is a rare inborn error of immunity that leads to early-onset lymphoproliferation, autoimmune cytopenias, multi-solid organ autoimmunity, hypogammaglobulinemia, and short…
  • Abstract Number: 037 • 2023 Pediatric Rheumatology Symposium

    Transcriptional Analysis of CD14+ Monocytes During Macrophage Activation Syndrome Highlights Role for Interferons and RNA Sensing in Monocytes

    Susan Canny1, Hannah DeBerg2, Griffin Gessay2, Ailing Lu3, Mary Eckert1, Andrea La Bella4, Susan Shenoi5, Joyce Hui-Yuen6, Betsy Barnes7 and Jessica Hamerman2, 1Seattle Children's Hospital, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Feinstein Institutes for Medical Research, Manhasset, NY, 4Northwell Health, Cohen Children's Medical Center, New Hyde Park, NY, 5Seattle Children's Hospital, Seattle, WA, 6Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 7Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (HLH), is a potentially fatal complication of rheumatic diseases. MAS is a dysfunctional hyperinflammatory…
  • Abstract Number: 0266 • ACR Convergence 2022

    Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression

    Judith Heutz1, Cleo Rogier2, Ellis Niemantsverdriet3, Susan van den Eeden4, Pascal de Jong5, Annemieke Geluk6 and Annette van der Helm-van Mil7, 1Erasmus Medical Center, Rotterdam, Netherlands, 2Erasmus MC, Rotterdam, Netherlands, 3LUMC, Leiden, Netherlands, 4Leiden University Medical Center (LUMC), Leiden, Netherlands, 5ErasmusMC, Hendrik Ido Ambacht, Netherlands, 6Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, 7Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Autoantibody responses rise years before onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA (1). Cytokine…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology